Strategic partnerships Eyenovia focuses on ophthalmic drug-device combinations with its Optejet platform and pursues out-licensing for additional indications, presenting partnerships opportunities with pharma, device integrators, and contract research organizations seeking eye care solutions.

Digital asset strategy Recent moves into blockchain and crypto custody, including a co-branded validator node and a CIO appointment, indicate a diversified investor relations and treasury management approach that may open conversation about digital asset services or fintech collaboration for their funding rounds.

Funding readiness A $50M PIPE financing and strategic hires signal active capital deployment and growth; sales teams can target biotech and ophthalmology stakeholders involved in ophthalmic device delivery and drug delivery collaborations seeking fresh financing or co-development deals.

Technology enablement Optejet device platform combined with a tech stack spanning iCIMS to Google Cloud suggests strong integration capabilities; opportunities exist to propose digital health, data integration, or cloud-enabled trials and regulatory submissions support for eye care programs.

Expansion potential Recent leadership changes in commercial operations and strategic advisory hires reflect upcoming go-to-market activity; identify prospects in ophthalmology clinics, pediatric eye care, presbyopia, and glaucoma spaces for device-augmented therapies and potential co-development or distribution arrangements.